Johnson & Johnson (NYSE:JNJ) Shares Acquired by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company raised its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 3.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 2,984,838 shares of the company's stock after buying an additional 92,927 shares during the period. The Manufacturers Life Insurance Company owned about 0.12% of Johnson & Johnson worth $431,667,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Bellwether Advisors LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter worth about $97,000. Quarry LP purchased a new position in Johnson & Johnson during the fourth quarter worth approximately $459,000. Shorepoint Capital Partners LLC grew its holdings in Johnson & Johnson by 0.3% in the fourth quarter. Shorepoint Capital Partners LLC now owns 35,284 shares of the company's stock valued at $5,103,000 after purchasing an additional 122 shares during the period. Mission Creek Capital Partners Inc. raised its stake in shares of Johnson & Johnson by 22.7% during the 4th quarter. Mission Creek Capital Partners Inc. now owns 34,659 shares of the company's stock worth $5,012,000 after buying an additional 6,416 shares during the period. Finally, Gerber Kawasaki Wealth & Investment Management lifted its position in shares of Johnson & Johnson by 3.7% during the 4th quarter. Gerber Kawasaki Wealth & Investment Management now owns 3,082 shares of the company's stock valued at $446,000 after buying an additional 110 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Trading Up 1.0 %

JNJ traded up $1.60 on Friday, hitting $156.06. The company had a trading volume of 3,072,670 shares, compared to its average volume of 9,599,042. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The firm has a market cap of $375.49 billion, a P/E ratio of 23.47, a PEG ratio of 2.56 and a beta of 0.49. The company's fifty day moving average price is $159.05 and its 200 day moving average price is $154.73. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. As a group, equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, May 27th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a yield of 3.33%. Johnson & Johnson's dividend payout ratio is 57.84%.

Analysts Set New Price Targets

Several research firms have issued reports on JNJ. Wells Fargo & Company decreased their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating on the stock in a report on Thursday, January 23rd. Stifel Nicolaus decreased their price target on shares of Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating on the stock in a research note on Thursday, January 23rd. Bank of America cut their price objective on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research note on Thursday, April 10th. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Finally, Raymond James reduced their price objective on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research note on Monday, April 14th. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $171.82.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 6,999 shares of the company's stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares of the company's stock, valued at $3,483,645.88. This represents a 25.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares of the company's stock, valued at $2,357,552.70. This represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company's stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.